Herantis has a product development portfolio focused in areas of unmet clinical need, based on internationally recognized science.
Our focus is on innovative, novel medicinal products for the treatment of indications with an unmet clinical need. We aim to develop our products through clinical Proof-of-Concept and partner with large pharmaceutical or biotech companies for late stage development and commercialization.
Drug development pipeline
|Product||Preclinical||Phase 1||Phase 2||Phase 3|
|CDNF for Parkinson’s disease||X||X||*|
|Lymfactin® for secondary lymphedema||X||X||**|
|CDNF for Amyotrophic Lateral Sclerosis***||X|
|CDNF for other neurodegenerative diseases***|
*Phase 1-2 study approved, patient recruitment begins in Q3/2017.
**Phase 2 clinical study application has been submitted to regulatory authorities.
***Promising preclinical data exist. Formal development has not been started.